Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 203 of the 205 references it cites were found in a registry or an index.

Calprotectin: from biomarker to biological function

Open access

Abstract

The incidence of inflammatory bowel diseases (IBD) emerged with Westernisation of dietary habits worldwide. Crohn’s disease and ulcerative colitis are chronic debilitating conditions that afflict individuals with substantial morbidity and challenge healthcare systems across the globe. Since identification and characterisation of calprotectin (CP) in the 1980s, faecal CP emerged as significantly validated, non-invasive biomarker that allows evaluation of gut inflammation. Faecal CP discriminates between inflammatory and non-inflammatory diseases of the gut and portraits the disease course of human IBD. Recent studies revealed insights into biological functions of the CP subunits S100A8 and S100A9 during orchestration of an inflammatory response at mucosal surfaces across organ systems. In this review, we summarise longitudinal evidence for the evolution of CP from biomarker to rheostat of mucosal inflammation and suggest an algorithm for the interpretation of faecal CP in daily clinical practice. We propose that mechanistic insights into the biological function of CP in the gut and beyond may facilitate interpretation of current assays and guide patient-tailored medical therapy in IBD, a concept warranting controlled clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2021-324855

Cites

203 of 203 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Calprotectin expression in the gut, adapted from reference 148. Mucosal calprotectin expression indicated by brown immunohistochemical staining is visualised in lamina propria immune cells and to a lesser extent the intestinal epithelium in ulcerative colitis (UC) and Crohn’s disease (CD), but not healthy controls (Ctrl).
Figure 1 Calprotectin expression in the gut, adapted from reference 148. Mucosal calprotectin expression indicated by brown immunohistochemical staining is visualised in lamina propria immune cells and to a lesser extent the intestinal epithelium in ulcerative colitis (UC) and Crohn’s disease (CD), but not healthy controls (Ctrl).CC BY-NC · PubMed Central
Figure 2 Proposed algorithm for the interpretation of faecal calprotectin (CP) concentration. No evidence-based algorithm has been established by controlled clinical trials. This algorithm is based on literature research and clinical experience. Note that faecal CP concentration reflects only one aspect of disease evaluation and should always be interpreted in conjunction with history and clinical and/or endoscopic examination. Panel A: In suspected inflammatory bowel diseases (IBD) (e.g. GI symptoms such as diarrhoea, bleeding or abdominal pain >4 weeks), faecal CP and a stool (pathogen) culture should be obtained. Repeated elevated faecal CP concentration (>40 µg/g) or persistent symptoms require further investigations. Faecal CP is also elevated during gastroenteritis (viral and bacterial), diverticular disease, drug-induced enteropathy and intestinal malignancies. IBS may also present with elevated CP but its probability decreases with higher concentrations (>150 µg/g). Panel B: In patients with an established diagnosis of IBD, faecal CP supports the diagnosis of active disease or remission. Faecal CP concentration <150 µg/g usually indicates remission with high accuracy. Elevated faecal CP concentration (>150 µg/g) raises suspicion for disease activity as elevated CP concentration is associated with increased risk of a clinically apparent disease flare in the following months. Based on the recently published Selecting Therapeutic Targets in Inflammatory Bowel Disease-II (STRIDE-II) recommendations values of 150–250 µg/g are considered as grey zone.174 In symptomatic patients with IBD, other causes for elevated faecal CP should be excluded (such as infection and drug-induced enteropathy) and endoscopy should be performed before switching medical therapy. *In immunocompromised patients, serological testing for cytomegalovirus (CMV), HIV and herpes simplex virus (HSV) may be obtained and history should exclude drug-induced enteropathy associated with non-steroidal anti-inflammatory drugs, proton-pump inhibitors, sartans, levodopa and rarely other drugs. **Alarm symptoms are defined by unintentional weight loss, night sweat, bloody diarrhoea and/or vomiting indicating upper and/or lower endoscopy.
Figure 2 Proposed algorithm for the interpretation of faecal calprotectin (CP) concentration. No evidence-based algorithm has been established by controlled clinical trials. This algorithm is based on literature research and clinical experience. Note that faecal CP concentration reflects only one aspect of disease evaluation and should always be interpreted in conjunction with history and clinical and/or endoscopic examination. Panel A: In suspected inflammatory bowel diseases (IBD) (e.g. GI symptoms such as diarrhoea, bleeding or abdominal pain >4 weeks), faecal CP and a stool (pathogen) culture should be obtained. Repeated elevated faecal CP concentration (>40 µg/g) or persistent symptoms require further investigations. Faecal CP is also elevated during gastroenteritis (viral and bacterial), diverticular disease, drug-induced enteropathy and intestinal malignancies. IBS may also present with elevated CP but its probability decreases with higher concentrations (>150 µg/g). Panel B: In patients with an established diagnosis of IBD, faecal CP supports the diagnosis of active disease or remission. Faecal CP concentration <150 µg/g usually indicates remission with high accuracy. Elevated faecal CP concentration (>150 µg/g) raises suspicion for disease activity as elevated CP concentration is associated with increased risk of a clinically apparent disease flare in the following months. Based on the recently published Selecting Therapeutic Targets in Inflammatory Bowel Disease-II (STRIDE-II) recommendations values of 150–250 µg/g are considered as grey zone.174 In symptomatic patients with IBD, other causes for elevated faecal CP should be excluded (such as infection and drug-induced enteropathy) and endoscopy should be performed before switching medical therapy. *In immunocompromised patients, serological testing for cytomegalovirus (CMV), HIV and herpes simplex virus (HSV) may be obtained and history should exclude drug-induced enteropathy associated with non-steroidal anti-inflammatory drugs, proton-pump inhibitors, sartans, levodopa and rarely other drugs. **Alarm symptoms are defined by unintentional weight loss, night sweat, bloody diarrhoea and/or vomiting indicating upper and/or lower endoscopy.CC BY-NC · PubMed Central
Figure 3 Calprotectin in the control of gut inflammation. (1) Inflammatory bowel diseases arise from a disrupted host-microbe interplay resulting in chronic remittent gut inflammation. (2) Tissue inflammation is driven by cytokines (yellow) activating innate and adaptive immunity. (3) Acute inflammation leads to the mucosal recruitment of neutrophil granulocytes (violet) which partly migrate into the gut lumen. Neutrophils constitutively express and release calprotectin (blue) which may fuel mucosal inflammation, as calprotectin drives neutrophil chemotaxis, induces the expression of endothelial adhesion molecules and activates pattern recognition receptors (e.g. Toll-like receptor 4 or receptor for advanced glycation end products) on innate and adaptive immune cells. Calprotectin in neutrophils modulates tissue adherence by microtubule rearrangements (green) and cytotoxicity by generation of reactive oxygen species via NADPH oxidase. (4) Calprotectin also harbours antimicrobial functions. Calprotectin allows chelation of essential divalent metal ions (e.g. calcium, iron or zinc) limiting growth of invasive and commensal gut bacteria. (5) Calprotectin represents a well-studied non-invasive (systemic and faecal) inflammatory biomarker in inflammatory bowel diseases due to its stability at room temperature, assay reproducibility and low costs. However, faecal calprotectin is also elevated during gut infection, other gastrointestinal diseases and in drug-induced enteropathy. ROS, reactive oxygen species.
Figure 3 Calprotectin in the control of gut inflammation. (1) Inflammatory bowel diseases arise from a disrupted host-microbe interplay resulting in chronic remittent gut inflammation. (2) Tissue inflammation is driven by cytokines (yellow) activating innate and adaptive immunity. (3) Acute inflammation leads to the mucosal recruitment of neutrophil granulocytes (violet) which partly migrate into the gut lumen. Neutrophils constitutively express and release calprotectin (blue) which may fuel mucosal inflammation, as calprotectin drives neutrophil chemotaxis, induces the expression of endothelial adhesion molecules and activates pattern recognition receptors (e.g. Toll-like receptor 4 or receptor for advanced glycation end products) on innate and adaptive immune cells. Calprotectin in neutrophils modulates tissue adherence by microtubule rearrangements (green) and cytotoxicity by generation of reactive oxygen species via NADPH oxidase. (4) Calprotectin also harbours antimicrobial functions. Calprotectin allows chelation of essential divalent metal ions (e.g. calcium, iron or zinc) limiting growth of invasive and commensal gut bacteria. (5) Calprotectin represents a well-studied non-invasive (systemic and faecal) inflammatory biomarker in inflammatory bowel diseases due to its stability at room temperature, assay reproducibility and low costs. However, faecal calprotectin is also elevated during gut infection, other gastrointestinal diseases and in drug-induced enteropathy. ROS, reactive oxygen species.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 205 references

Cited by

See all 551

Metadata

Authors
Jukic, A., Bakiri, L., Wagner, E. F., Tilg, H., & Adolph, T. E.
Affiliations
  • Innsbruck Medical University (AT)
  • Medical University of Vienna (AT)
Corresponding author
Adolph, Timon E.
Venue
Gut
Publisher
BMJ
Published
2021-06-18
Volume
70
Issue
10
Pages
1978-1988
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W3173062350
Cited by
500
References
205
Citations by year
2026: 91 · 2025: 114 · 2024: 132 · 2023: 103 · 2022: 54 · 2021: 5
FWCI
10.90
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Austrian Science Fund (FWF P33070)
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › S100 Proteins and Annexins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Calpain Protease Function and Regulation
Keywords
calprotectin, fecal calprotectin, inflammatory bowel disease, Crohn's disease, ulcerative colitis, S100A8, S100A9, mucosal inflammation, non-invasive biomarkers, disease activity monitoring, personalized treatment
MeSH terms
Algorithms, Feces, Humans, Predictive Value of Tests, Sensitivity and Specificity, Inflammatory Bowel Diseases, Biomarkers, Leukocyte L1 Antigen Complex

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Calprotectin: from biomarker to biological function. https://app.cochat.ai/papers/10.1136/gutjnl-2021-324855
The paper
Jukic, A., Bakiri, L., Wagner, E. F., Tilg, H., & Adolph, T. E. (2021). Calprotectin: from biomarker to biological function. Gut. https://doi.org/10.1136/gutjnl-2021-324855

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.